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ABSTRACT
Pharmaceuticals escape wastewater treatment plants and contaminate aquatic
environments; there is increasing concern about the exposure of aquatic organisms
and the combined toxicity of this complex mixture of chemicals.

Four human

pharmaceuticals were chosen for this study: all are water-soluble and thus,
complications of solvent effects are eliminated, and all are commonly used in the U.S.
and have been detected in the aquatic environment. A 48-hour motility assay of <24
hour-old Daphnia magna neonates was used to examine the effects of a mixture of
commonly-used pharmaceuticals. Due to the lack of aquatic toxicity data, LC50 (lethal
concentration at the 50th percentile) and NOAEL (no observed adverse effect level)
concentrations of propranolol, metoprolol, terbutaline, and metformin were estimated.
The first part of this study investigates the acute toxicity of these four drugs –
two beta blockers, a bronchodilator and an antihyperglycemic drug, respectively –
using high concentration binary mixtures according to methods well-established in
the literature. These methods are aimed at establishing the nature of the interactions,
determining whether the drugs are synergistic (higher toxicity) or antagonistic (lower
toxicity) when given in combination. The interaction of metformin and metoprolol
was shown to be antagonistic.
The second part of this study examines mixture toxicity again, but at low,
environmentally-relevant concentrations in complex mixtures. Synergism and
antagonism were observed in these mixtures. In contrast to the results described for
high-concentration experiments metformin and metoprolol were synergistic.
Additionally, metformin and metoprolol together (but not separately) were synergistic
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with propranolol. Terbutaline and propranolol were also synergistic, but the addition
of either metformin or metoprolol to the mixture antagonized the combined toxicity
of the terbutaline/propranolol mix. None of these relationships would be predicted by
the drugs‟ mechanism of action in humans.
These results suggest that mixture toxicity evaluated at high (LC50)
concentrations may not predict the interactions observed at low, environmentallyrelevant (NOAEL) concentrations. This calls into question the standard methods for
evaluating mixture toxicity. Additionally, frequent use of pharmaceuticals by
consumers coupled with imperfect methods of wastewater treatment will likely
increase pharmaceutical residue in the aquatic environment. Future experiments will
be aimed at determining the mechanism of drug interactions observed in this study.
Furthermore, it should also consider the toxicological impact of degradation products
of pharmaceutical mixtures on the overall aquatic ecosystem and human health.
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INTRODUCTION
Pharmaceuticals and their metabolites enter the aquatic environment from
leaching, excretion of human waste and through wastewater systems (Kim et al.,
2007; Dussault et al., 2008; Nikolaou et al., 2007). These substances and their
metabolites have been detected in many countries in surface water, ground water,
drinking water, seawater, discharge from sewage treatment plants (STP), wastewater
treatment plants (WWTP), and soil sediments. Some of the drugs resist degradation
and are found in the environment in their parent, active form (Fent et al., 2006;
Hernando et al., 2006; Kim et al., 2007). Unaltered or metabolized pharmaceuticals
are excreted from the patient through urine and feces and end up in the sewage
system. However, wastewater treatment plants fail to completely degrade all
pharmaceuticals, leaving the water contaminated with some pharmaceutical drugs
(Langford, 2009, Dokianakis, 2004).
With improved medical treatment and rising human population the number of
prescriptions dispensed per year is also steadily increasing (Huggett et al., 2003A;
Huggett et al., 2003B; Koplin et al., 2002). This in turn increases the amount of
pharmaceuticals that ends up in the environment and is an emerging concern. In 2008,
the total number of drugs ordered or prescribed in the U.S. was 2.3 billion
(FASTSTATS, 2011). Even if some pharmaceuticals have relatively short
environmental half-lives they are assumed to be “pseudopersistents” due to their polar
and non-volatile nature which prevents them from escaping the aquatic realm
(Hernando et al., 2006). Additionally, the constant input of pharmaceuticals may also
induce toxic effects even in trace amounts due to high biological activity at the site of
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action. Studies have shown that some pharmaceuticals which are specifically
designed for human target receptors have resulted in sublethal toxicity (cancer and
reproductive damage) in organisms with genetic similarities due to potent interaction
(Koplin et al., 2002).
The environmental concentrations of these drugs are usually detected at trace
levels (ng/L or ppt); recent published literature supports this estimate (Kolpin et al,
2002; Kolpin et al, 2004; Stackelberg et al., 2007; Pedrouzo et.al., 2008; Gómez et.
al., 2006; Gibs et al., 2007; Joakim Larsson et al., 2007; Kosonen et al., 2009).
Although low, these concentrations may be significant enough to induce toxic and
synergistic effects on aquatic species due to the drugs‟ continual influx and
persistence in the environment (Hernando et al., 2006; Isidori et al., 2009; Kim et al.,
2007). Additionally, organisms are exposed to a mixture of chemicals in the
environment. This may result in different combined effects: simple addition of a toxic
effect (noninteractive or additive action), an effect which is less than the sum of the
separate constituents (antagonism) and toxic effects which may exceed the total
additive effects of the separate constituents (synergism) (Otitoloju, 2002).
Published toxicity data exist for some of the drugs tested; in general, LC50
values are quite high but are also highly variable depending on experimental
conditions (Kim et. al, 2007; NOAA, 2006; Park, 2005). However, even the
comparatively low environmental concentrations may be significant enough to induce
toxic and synergistic effects on non-target species due the continual influx and
persistence in the environment (Hernando et al., 2006; Isidori et al., 2008; Kim et al.,
2009). Frequent prescriptions of drugs account for this constant influx. The full extent
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of the aquatic exposure to these pharmaceuticals is still unknown. LC50 values have
been published for the pharmaceuticals in this study: propranolol and metoprolol have
LC50 values for Daphnia magna of 1.6 mg L-1 (Dzialowski, 2006) and 64 mg L-1
(Huggett, 2002) respectively.

Types of Common Pharmaceuticals
Human and veterinary drugs are continuously released into the environment
from leaching/excretion of human waste, direct disposal, sewage treatment plants
(STPs), manufacturing processes, animal excreta, and surface runoff (Hernando et al.,
2006; Kim et al., 2009; Dussault et al., 2007).. Many of these drugs resist degradation
and remain in the environment at trace levels. However, pharmaceuticals constantly
enter and persist in the environment due to the high use of drugs prescribed in the
United States.

Studied Pharmaceuticals
This

study

focuses

on

four

commonly

prescribed,

water-soluble

pharmaceuticals used in the United States: two beta blockers, a bronchodilator and an
anithyperglycemic drug (shown in Table 1). Beta blockers such as propranolol,
metoprolol, and nadolol have been detected in European effluent discharges (Ternes,
1998). More recently the wastewater effluent samples from Texas, New York, and
Mississippi detected β-adrenergic receptor antagonists at levels as high as 1.9 µg L-1
(Huggett et al., 2003B). The site of action for beta blockers is on β-adrenergic
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receptors, a class of receptors vital for the normal function of the sympathetic branch
of the vertebrate autonomic nervous system (Huggett et al. 2002).
Metoprolol (structure shown in Figure 1) is a β1 selective andrenoceptor
blocking agent which is widely used to treat high blood pressure or hypertension. It
ranks as the #9 most commonly dispensed drug in the United States (Rxlist, 2011).
Approximately 2% of the metoprolol entering the wastewater treatment stems from
hospital effluent (Langford et al., 2009). The amount of metoprolol present in sludge
ranges from 0.026 µg/L to 0.063 µg/L with a mean of 0.039 µg/L (Radjenović et al.,
2009). According to a study conducted by Huggett et al. (2003B), metoprolol was
detected in wastewater treatment plants with the highest U.S. concentration effluent
reported at 1.9 µg L-1.

Figure 1: Example of beta blocker - Metoprolol
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Propranolol (structure shown in Figure 2) is a β adrenergic receptor blocking
agent which is also used to treat hypertension, angina, post-traumatic stress, and
reduce the severity and frequency of migraine headaches. More than 50 million
Americans are diagnosed with hypertension and more than 4 million suffer from
angina (Huggett et al., 2002). Around 11% of the propranolol entering the wastewater
treatment comes from hospital effluent; this may cause minor inhibition on the
performance of nitrite oxidizing bacteria (Langford et al., 2009; Dokianakis et al.,
2004). The propranolol level found in sludge ranged from 0.072 µg/L to 0.54 µg/L
with a mean of 0.347 µg/L (Radjenović et al., 2009). Furthermore, propranolol was
detected in wastewater treatment plants with the highest U.S. concentration effluent
reported at 1.9 µg L-1 (Huggett et al., 2003B).

Figure 2: Example of beta blocker - Propranolol

Terbutaline (structure shown in Figure 3) is a β-adrenergic agonist
bronchodilator which is used to treat asthma, chronic bronchitis, emphysema and
other respiratory diseases. A study conducted by Làven et al. (2009) detected
terbutaline in influent and effluent wastewater at a concentration of around < 0.21
7

µg/L and <0.085 µg/L respectively. Additionally, the study also showed that the
concentration levels were reduced to <0.12 µg/L in ozone treated effluent and to <
0.080 µg/L in wastewater passed through MBR (membrane bioreactor).

Figure 3: Example of bronchodilator - Terbutaline

Metformin (structure shown in Figure 4) is an antihyperglycemic drug which
has been used to treat non-insulin-dependent (type 2) diabetes for more than 40 years
(Salpeter et al., 2003). Metformin was detected in U.S. stream samples with a median
of 0.11 µg/L and a maximum of 0.15 µg/L (Koplin et al., 2002). In the United States,
metformin ranks as the 17 most commonly dispensed pharmaceutical (Rxlist, 2011).

Figure 4: Example of antihyperglycemic drug – Metformin
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Table 1. Pharmaceuticals tested in the current experiment.
Generic

Brand Name

Use

Mechanism of

Name

Extent of Use1

Action

Metformin

FORTAMET®

Diabetic drug

GLUMETZA®

Antihyperglycemic # 17 by
drug

prescriptions
dispensed

Metoprolol

LOPRESSOR®

Treatment of

1-sel blocker

# 9 by

cardiovascular

prescriptions

disease,

dispensed

hypertension
Propranolol

INDERAL®

Treatment of

Non-sel -blocker

hypertension
Terbutaline

TERBUTALINE

Bronchodilator

 2-agonist

SULFATE
1

Data obtained from Rxlist, 2011

Confounding Factors
Organisms and ecosystems are exposed to a mixture of chemicals in the
environment which may result in different combined toxic effects: simple addition,
synergism or antagonism. However, the complication of mixture toxicity of
pharmaceuticals in the environment is still not fully understood (Otitoloju, 2002).
Additionally, pharmaceuticals may reach the aquatic environment by bypassing the
STP effluent, thus directly causing bioaccumulation for organisms downstream
(Dokianakis, 2004). However, there is still a lack of toxicity information on the
interaction of commonly used pharmaceuticals in the aquatic environment (Koplin et
al, 2002).
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Wastewater Treatment Processes
Wastewater treatment speeds up the natural process of water purification and
is one of the most common forms of pollution control in the United States. The two
main stages in wastewater treatment are primary and secondary treatment. Aerobic
bacteria can decompose naturally occurring organic matter in the environment.
However, the biological oxygen demand needed to decompose the waste produced by
humans would be too high for naturally occurring bacteria without the help of
wastewater treatment plants.
The primary wastewater treatment (as shown in Figure 5) starts with a bar
screening process which removes twigs, rags and other large debris. Next it is passed
„downstream‟ through a circular grit chamber where the cinders, sand, and small
stones are spun out. The suspended solids in the wastewater are then allowed to settle
to the bottom of the sedimentation tanks and the resulting sludge is removed (US
EPA, 1998; MDC, 2011).
Biological treatment is used in secondary wastewater treatment (as shown in
Figure 6) because it is effective on bacteria, contaminants, fungi and protozoa.
Around 85% of the organic matter in sewage is removed by using the bacteria
present in the sludge (US EPA, 1998).
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Figure 5: Primary wastewater treatment (MDC, 2011)
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Figure 6: Secondary wastewater treatment (MDC, 2011)
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Testing toxicities of mixtures
The standard method for evaluating mixture toxicity measures the toxicity of
binary mixtures at high concentrations (around their LC50s). However, this does not
represent the „real‟ environment. Thus, pharmaceuticals are also tested in low
concentration, binary and more complex mixtures.

Analyses of ecotoxicity data
In this research study, the data obtained from the tests were analyzed with the
help of a TU (Toxic Unit) model developed by Brown (1968) and Sprague (1970).
This provides a graphical representation of the results. The number of toxic units
associated with each of the constituents of the mixture was calculated as shown
below:

Where TUA: Toxic Unit of substance A in the mixture.

If the sum of the TU of all the constituents in the mixture is equal to 1 then the
interactions are additive. If the sum of constituents is less than one the interactions are
antagonistic and if the sum is greater than 1 the interaction is synergistic.
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Isobologram representation
Sprague (1970) described a method by which the interactions of the 2substance mixtures „A‟ and „B‟ could be represented in two dimensions. The curve is
a straight line as shown in Figure 7(a) if the effect is additive. However as shown in
Figure 7(b), if the effect is synergistic, the isobole of the AB mixture is located below
the additivity isobole (lower left); whereas, if the effect is antagonistic, the isobole of
the mixture is located above the isobole of additivity (Otitoloju, 2002; Warne, 2003).

(b)

(a)

1
Amount of Chemical „B‟ (TUs)

Amount of Chemical ‘B’ (TUs)

1

Antagonism

Synergism

1
Amount of Chemical „A‟ (TUs)

Actual toxicity of a mixture

Line of additivity

1
Amount of Chemical „A‟ (TUs)

Figure 7: Example of isoboles (a) showing additivity and the domains of antagonism
and synergism, (b) highlighting a variation of interactions between two substances as
a function of their ratio (Warne, 2003).
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In the current study, five different mixture ratios of each binary pair were
prepared (20:80, 40:60, 50:50, 60:40, and 80:20). Each of these mixture ratios was
tested in triplicate using six different concentrations around the mixture LC50
according to the method outlined by Panouillères et al. (2007). For the data analysis
of these mixture experiments, a two-step process was used: the concentrationresponse relationships were determined and an isobole analysis was used to assess the
interaction of the two drugs in the mixture.
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RESEARCH OBJECTIVE
This research study compares the results from testing mixtures in two ways:
1) High concentration, binary mixtures
2) Low concentration, binary and more complex mixtures

High concentration, binary mixtures
The first part of the study analyzes the effects of commonly used
pharmaceuticals in binary mixtures on Daphnia magna.
determined for each drug on Daphnia magna.

First, the LC50 will be

Subsequently, mixtures of

pharmaceuticals will be used to assess possible synergism and antagonism using
methods well-established in the literature.

Low Concentration, binary and more complex mixtures
The second part of the study seeks to better understand mixture toxicity at
environmentally relevant concentrations. It is possible that interactions at low
environmentally relevant concentrations will be different that those at high
concentrations. This would call into question the standard methods used to assess
mixture toxicity. However, there is limited information available on the toxicological
effects of pharmaceuticals in the environment and it is vital to continue research to
understand these interactions in greater depth.
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MATERIALS AND METHODS
Stock solutions of 100g/L were prepared in hard water and stored at 4° C until used.
Lower concentrations were prepared by serial dilution.
o β1 selective andrenoceptor blocking agent: Metoprolol (Sigma-Aldrich)
o β-adrenergic receptor blocking agent: Propranolol (Sigma-Aldrich)
o β-adrenergic agonist bronchodilator: Terbutaline (Sigma-Aldrich)
o Antihyperglycemic drug: Metformin (Sigma-Aldrich)

Daphnia magna
Daphnia magna were obtained from Aquatic Research Organisms (Hampton,
NH). Acute toxicity tests were performed in hard water according to Standard
Methods (1998). Ten neonates (<24 hr old) were placed in test tubes with 10 mL of
drug solution prepared in hard water. Daphnia were incubated at room temperature
and the motile daphnia were counted after 48 hrs. Each of the tests was performed in
triplicate.

Determination of LC50 values
Incubations were performed as described above, using 5 concentrations
around the LC50 value. For Daphnia Magna, 48-hr LC50 values for the 24-hr old
larvae were determined by probit analysis.

17

Determination of NOAEL (No Observed Adverse Effect Level)
For each drug that was used in this study the NOAEL (the highest
concentration tested that causes no toxicity) was determined.

Preparation of Hard Water
Hard water was prepared according to the Standard Methods (Eaton, 1998).
To prepare 4 L of hard water using DDI (distilled deionized water), the following
amounts of salts (as shown in Table 2) were used:

Table 2. Amount of salt (by weight) needed to make 4 L of hard water
Salt

Formula

4L

Sodium bicarbonate

NaHCO3

0.768 g

Calcium sulfate dehydrate

CaSO4 • 2H2O

0.480 g

Magnesium sulfate heptahydrate

MgSO4 • 7H2O

0.737 g

KCl

0.032 g

Potassium chloride

The salts were added to distilled deionized water in a glass Erlenmeryer flask
with a stir bar and then placed on a magnetic stir plate for at least 48 hours before
experiments. Water was aerated by bubbling air through in order to equilibrate the
carbonate buffer.
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RESULTS AND DISCUSSION
This study exposed the test organism, Daphnia magna, to varying
concentrations of commonly used pharmaceuticals to assess the toxicity of
pharmaceuticals in the environment. The pharmaceuticals were tested in high
concentration binary mixtures and at low concentration for binary and more complex
mixtures.

LC50 Value Determination
The LC50 value was experimentally determined for each drug due to the lack
of information available on the aquatic toxicity of these pharmaceuticals to Daphnia
magna and to determine concentrations needed for mixture experiments. The LC50
values determined for metformin, metoprolol and propranolol were 87.5 ppm, 175
ppm and 3.9 ppm respectively. These LC50 concentrations were used in subsequent
high-concentration mixture toxicity experiments.

High-concentration Mixture Toxicity
Three binary mixtures BC, BD and CD were tested, where B = Metformin, C
= Metoprolol and D = propranolol. The isobole parameters for the binary mixtures
tested with Daphnia magna are shown below.
If Figure 8 is compared to Figure 7 (b) the results indicate that the interaction
between high concentration binary mixture of metformin and metoprolol is
antagonistic (it lies above the line of additivity).
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1
0.9
0.8
0.7
TUC
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1
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Figure 8: Isobolic representation of estimated dose combination for binary mixture of B =
Metformin, C = Metoprolol, TU = Toxic Unit, tested with Daphnia magna.
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0.6
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TUB

Figure 9: Isobolic representation of estimated dose combination for binary mixture of
B = Metformin, D = Propranolol, TU = Toxic Unit, tested with Daphnia magna.
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Both Figure 9 and Figure 10 show the isobolic representation for binary
mixtures of BD (metformin, propranolol) and CD (metoprolol, propranolol). A line of
additivity is not observed in these two figures. A possible reason for this could be that
propranolol is very potent and its presence in the mixture overshadows the TU (Toxic
Unit) for the other substance. Future work with terbutaline, which has an LC50 around
the same order of magnitude as metoprolol and metformin will be helpful in
elucidating additional interactions and addressing this hypothesis.

20
18
16
14
TUD

12
10
8
6
4
2
0
0

0.1

0.2

0.3

0.4

0.5

0.6

TUC

Figure 10: Isobolic representation of estimated dose combination for binary mixture of
C = Metoprolol, D = Propranolol, TU = Toxic Unit, tested with Daphnia magna.
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NOAEL Tests
The NOAEL tests were performed first on all four pharmaceuticals to
determine the concentration at which the average percentage survival for Daphnia
magna was around 100%. The results of the test determined the NOAEL levels for
each drug as follows: terbutaline (100 ppm), metformin (50 ppm), metoprolol (50
ppm) and propranolol (1 ppm).

Low-concentration Mixtures
Daphnia neonates were incubated for 48 hours at room temperature with the
simple and complex mixtures and survival was recorded to assess toxicity. As shown
in Figure 11, almost all of the neonates survived at the NOAEL concentrations with
around 100% survival. However, when metformin and metoprolol were added to
terbutaline, a synergistic effect was observed and the average percentage of survival
decreased to around 56%. Furthermore, adding propranolol to this mixture lowered
the survival rate of Daphnia magna even more to around 25%. A similar synergistic
effect was seen when metoprolol and propranolol were added to metformin where the
average survival percentage decreased to around 38%.
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120%

Average % survival

100%

80%

60%

40%

20%

0%
control

Terbutaline

Metformin

Metoprolol

Propranolol

Terbutaline,
Metformin,
Metoprolol,
Propranolol

Terbutaline,
Metformin,
Metoprolol,

Metformin,
Metoprolol,
Propranolol

Solutions of pharmaceutical mixtures

Figure 11: Synergystic effect of Terbutaline (100 ppm), Metformin (50 ppm), Metoprolol(50
ppm) and Propranolol(1 ppm) mixtures on survival of 24 hour neonate Daphnia magna in a 48
hour exposure.
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Solutions of pharmaceutical mixtures

Figure 12: Synergistic effect of Terbutaline (100 ppm), Metformin (50 ppm),
Metoprolol (50 ppm) and Propranolol (1 ppm) mixtures on survival of 24 hour
neonate Daphnia magna in a 48 hour exposure.
Mixtures where metformin and metoprolol occurred together (but not
individually) with propranolol demonstrated synergistic effects (see Figure 12 and
Figure 13). Terbutaline and propranolol were also synergistic; however, the addition
of either metformin or metoprolol to the mixture antagonized the combined toxicity
(see Figure 12 and Figure 14). In the mixture of all four drugs, the synergistic effect
observed was of the highest magnitude and the average survival percentage dropped
from 100% in control to around 23%.
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Figure 13: Synergistic effect of Metformin (50 ppm), Metoprolol (50 ppm) and Propranolol (1
ppm) mixtures on survival of 24 hour neonate Daphnia magna in a 48 hour exposure.
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Figure 14: Synergistic effect of Terbutaline (100 ppm), Metformin (50 ppm) and Metoprolol (50
ppm) mixtures on survival of 24 hour neonate Daphnia magna in a 48 hour exposure.
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In contrast to Figure 8, the low concentration complex mixture exposure (see
Figure 13) suggests that the interaction of metformin and metoprolol at
environmentally relevant concentrations is synergistic. This underscores an important
point: the standard method for assessing mixture toxicity, using high concentrations
of binary mixtures, does not accurately represent the „real‟ environment. The
interaction between chemicals in a mixture may be completely different at low,
environmentally-relevant concentrations.
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CONCLUSION
The differing metoprolol-metformin interactions shown in this study for high
concentration and low concentration mixtures suggests that perhaps studying
environmentally relevant exposures may be a more accurate representation of what
happens in the aquatic environment. Future work will be aimed at testing additional
drugs in binary and more complex mixtures to further elucidate this conclusion.
Toxicity endpoints other than mortality, including changes to growth and
development, may occur at concentrations lower than LC50 values, or if chronic
exposure occurs. In the experiments each drug was incubated at the NOAEL
concentration: terbutaline (100 ppm), metformin (50 ppm), metoprolol (50 ppm) and
propranolol (1 ppm). Synergism was observed in many of the mixtures, as shown
above.
Additionally, further experiments need to be conducted with more complex
mixture combinations using different concentrations and future studies should be
directed towards elucidating the mechanisms of the observed toxicity and drug-drug
interactions. Additional studies should also consider the toxicological impact of
degradation products of drugs on aquatic life, the impact of drugs on other organisms
and on the complete aquatic ecosystem. Future studies could also focus on utilizing
better analytical techniques to reduce the experimental error and get more accurate
and precise results. Furthermore, some pharmaceuticals target a specific biochemical
site of action and the toxic effects observed may differ based on the sensitivity of the
organism. Subsequently, pharmaceuticals may not be harmful to particular organisms;
however, it may cause sub-lethal toxicity in organisms with genetic similarities. Thus,
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future studies could assess synergism and antagonism in toxicity of mixtures of
pharmaceuticals on other aquatic organisms.
Due to the persistence and increasing use of pharmaceuticals, they are
increasingly more likely to be an environmental concern. Thus the research done in
this field could form the foundation for better environmental regulation for
pharmaceuticals in the wastewater and aquatic environment, particularly taking
mixture effects into account.
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